Clinical Trial Update: Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating safety and tolerability of lucinactant for inhalation in preterm neonates (26 to 28 weeks PMA) with respiratory distress syndrome was…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Lucinactant (lucinactant)

Snippet

Sponsor: Windtree Therapeutics | Conditions: Respiratory Distress Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2019-07-23